Flexion Therapeutics Claimed Company
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. read more
Kerry Wentworth ā Chief Regulatory Officer at Flexion Therapeutics
Executive Bio
Ms. Wentworth brings more than 20 years of experience in both domestic and international Regulatory Affairs that spans early and late development across multiple therapeutic areas. Prior to joining Flexion, Ms. Wentworth served as Vice President, Clinical, Regulatory and Quality at Agenus, Inc., where she was responsible for leading all global regulatory and clinical development efforts for nearly 10 years. Previously, Ms. Wentworth led the Regulatory and Quality function for Genelabs Technologies, Inc., where she was responsible for advancing their lead program through Phase 3 development and into the registration phase with FDA and EMA. Ms. Wentworth also held positions of increasing responsibility within Regulatory Affairs at Genzyme. Ms. Wentworth holds a B.S. in pre-veterinary medicine from the University of New Hampshire.
Executive Team Culture Ratings from Flexion Therapeutics Employees
TOP
5%
Flexion Therapeutics' Executive Team scores in the Top 5%
of similar sized companies on Comparably
of similar sized companies on Comparably
Flexion Therapeutics' Executive Team at a Glance
Based on 105 ratings, Flexion Therapeutics' employees are very satisfied with their Executive Team and give them an āA+ā or 95/100. On average, Women provided higher ratings for their Executive Team compared to Men. Also, the IT department thinks more highly of the Executive Team relative to the HR department.
Flexion Therapeutics' Executive Team ranks in the Top 5% of other companies in Boston and Top 5% of other companies on Comparably that also have 201-500 Employees.
×